


# INTERNET NEWS

BS. ĐỖ NGỌC ANH KHOA


# Making Tumors Tastier for the Immune System



Researchers at The University of Texas MD Anderson Cancer Center have developed a nanotechnology platform that can make cancer cells more vulnerable to immune attack in the body. The researchers call their system the bispecific tumor-transforming nanoconjugate (BiTN) platform.

The idea is to make solid tumors more appealing for the immune system by attaching a molecule that acts as an “eat me” signal to white blood cells. This molecule is called signaling lymphocytic activation molecule family member 7 (SLAMF7) receptor and is more commonly found on cancer cells in blood cancers, which explains the relative success of existing immune therapies in those cancer types. Solid tumors are not typically as susceptible to the immune system, so these researchers decided to make them more appealing by attaching SLAMF7 to their surface.

Immunotherapies have changed the way that many cancers are treated. There is something pleasing about activating our own immune system to attack a cancer, and it may avoid the need to administer large doses of toxic chemotherapy drugs that can have a wide spectrum of unacceptable side-effects. Our immune cells can be highly effective at sniffing out and destroying cancer cells, but in some instances they may need a little help to identify the tumor.




Immunotherapies have changed the way that many cancers are treated. There is something pleasing about activating the immune system to attack a cancer, and it may avoid the need to administer large doses of toxic chemotherapy that can have a wide spectrum of unacceptable side-effects. Our immune cells can be highly effective at sniffing out and killing cancer cells, but in some instances they may need a little help to identify the tumor.

In the case of blood cancers, such as leukemia and lymphoma, immune therapies are often relatively successful. In part because these cancers tend to express SLAMF7 on their cell surfaces, and this is a key cue for the immune system to identify them as worthy of attack and acts as sweet honey for phagocytic white blood cells. In solid tumors, however, the efficacy of immune treatments tends to be more mixed, and there is a need to improve this.

Researchers have developed a nanotechnological system that can label solid tumor cells with SLAMF7, making them much tastier to white blood cells. The system is called bispecific tumor-transforming nanoconjugate (BiTN) and it consists of a tumor-specific antibody that is conjugated with SLAMF7.

# Smart Socks Help Prevent Falls Among At-Risk Patients





Researchers at the Ohio State University Wexner Medical Center have tested the PUP (Patient is Up) Smart Socks, developed by a company called Palarum, in their ability to reduce falls among at-risk patients. The socks contain pressure sensors that alert caregivers when a patient is attempting to stand up. This can include situations such as a patient getting out of bed to go to the toilet. The socks can wirelessly communicate with the system, which then alerts the caregivers that are closest to the patient, so that they can provide assistance as soon as possible. The recent study showed that the system significantly reduced fall rates in patients at risk of such incidents.

Falls can spell serious consequences for frail and vulnerable patients, and can often be the start of a downward health spiral. It is not possible to monitor high-risk patients every minute of the day, but wireless technologies are well-suited to fulfill an assistive role in this context.

Falls often happen when a high-risk patient attempts to get out of bed to use the restroom, and this is the time that having a caregiver to assist can dramatically reduce the risk of such incidents. Current approaches sometimes involve pressure sensors in beds, but these frequently give false alarms, leading to alarm fatigue and reduced effectiveness of such systems.

# AR Headset Helps Surgeons Place Implants




Enovis, a medtech company based in Delaware formerly known as DJO, recently announced the launch of ARVIS (Augmented Reality Visualization and Information System), an augmented reality technology that is designed to assist surgeons during implant placement in the hip and knee. The hands-free technology consists of an eyepiece that is mounted on a surgical helmet that provides the surgeon with real-time information about the position of the implant with respect to patient anatomy.

It can be difficult for a surgeon to accurately track patient anatomy obscured by a variety of obstacles, such as sterile drapes. The goal behind this new device is to allow a computer to assist with the procedure while impacting the surgeon as little as possible with a hands-free design. The augmented reality system is smaller and less cumbersome than many existing surgical robotic systems.

It allows highly experienced surgeons to perform procedures on themselves rather than largely outsourcing them to a machine. The new system provides insights that only a machine could. The technology includes infrared cameras that can track the position of surgical tools and the surgeon can mark specific landmarks on the patient anatomy to help orient the system at the beginning and throughout a procedure.

# Non-Invasive Spinal Modulation for Cerebral Palsy



SpineX, a medtech company based in California, has developed the Spinal Cord Innovation in Pediatrics (SCIIP) device, a non-invasive spinal cord neuromodulation technology that is intended to treat children with cerebral palsy. The technology is designed to be used in conjunction with activity-based neurorehabilitation therapy with the goal of improving functional movements in such children. Through transcutaneous spinal cord neuro-stimulation, the technology aims to modulate dysfunctional brain and spinal cord connectivity. In a recent pilot study, the company reports that 16 pediatric patient volunteers, with a range of cerebral palsy severities and ages, demonstrated improved sensorimotor function after treatment with the device.

Cerebral palsy is a group of movement disorders that typically occur because of damage to the developing brain with symptoms affecting posture, gait, and balance. At present, there are no therapies to effectively treat cerebral palsy. Some patients undergo invasive surgery in an attempt to address certain symptoms, such as spasticity, but there is a clear need for new effective treatments and less invasive alternatives.

# Conductive Cotton Thread for Wearable Sensors in Commercial Textiles

Imperial College London researchers created a conductive cotton thread that can undergo a computerized embroidery process for incorporation into commercially available textiles, such as t-shirts and face masks. The thread, called PECOTEX, is used to create wearable health sensors, such as heart rate monitors, breathing monitors and even gas sensors, including ammonia sensors for the breath, which can provide information on liver and kidney function.


Embroidered sensors are machine washable and are stronger and more durable than previously developed conductive threads. The major benefit, though, is the thread's compatibility with industrial computerized embroidery machines, meaning that it can easily and inexpensively be incorporated in a wide range of commercially available textiles.




Incorporating health sensors into everyday clothing or face masks makes a lot of sense. After all, we wear such items everyday and they are frequently in close contact with our skin. However, if clothing that contains health sensors is to become widely adopted, it would be beneficial if such technologies are compatible with existing industrial manufacturing processes.

The less 'specialized' a technology is to manufacture, the less expensive it is and it is more likely that it will be used by many people. This is the impetus for this technology, PECOTEX thread, which aims to bring health sensing clothing to a larger pool of users.

Imperial researchers created the PECOTEX thread by crosslinking poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS) and cotton thread with divinyl sulfone as a crosslinker. The thread is very inexpensive, costing just a few cents per meter, which can then go on to form multiple sensors in a garment.

## Scanning Electron Images









# Multi-Center Liquid Embolic Study Concludes



*Baseline image of contrast flowing through right renal artery and tumor. Christchurch Hospital, Christchurch, New Zealand*



*Occlusion of right renal artery using GPX Embolic Device. Christchurch Hospital, Christchurch, New Zealand*



at Lake City (UT) – Fluidx Medical announces the completion of a multi-center clinical trial examining the broad application of their low viscosity liquid embolic agent, GPX<sup>®</sup>. Embolization is a procedure in which arterial or venous blood supply is intentionally blocked. With the positive conclusion of this trial, the Fluidx embolic platform has a promising future. “The completion of this trial gives GPX a lot of momentum,” said Russ Bjorklund, Vice President of Strategy and Marketing. “Physician feedback surpassed expectations, and the results of this trial give us a great deal of confidence in GPX as a platform technology with demonstrated value in peripheral vascular and interventional oncology, and opportunities for expansion to neurovascular applications.”

A common concern with liquid embolics is that the delivery microcatheter tip may become entrapped in solidifying embolic following deployment. But the unique GPX material does not entrap existing delivery microcatheters, and no entrapment was observed during the study. Because clinicians weren’t concerned with GPX-caused microcatheter entrapment, they were able to take their time during arterial delivery to ensure complete occlusion of the targeted region.

GPX technology is a low viscosity, aqueous-based solution that solidifies into a durable embolus upon delivery without polymerization or dimethyl-sulfoxide (DMSO) precipitation.\* The platform is expected to bring simple preparation and controllable material delivery to several embolic applications. The device is packaged in a ready-to-use syringe, can be prepped tableside by the clinician in about 30 seconds, and may be delivered through standard microcatheters (no complex mixing systems or special delivery catheters are necessary).

THANK YOU